免疫检查点抑制剂在非小细胞肺癌治疗中的应用  

Application of Checkpoint Inhibitors in the Treatment of Nonsmall Cell Lung Cancer

作　　者：袁连方[1] 蔡琦玲[1] 邵娜[1] 

机构地区：[1]天津市南开医院呼吸内科,天津300100

出　　处：《继续医学教育》2017年第1期125-128,共4页Continuing Medical Education

基　　金：天津市卫生和计划委员会基金资助项目(2015026)

摘　　要：近年来,非小细胞肺癌的预后仍较差,而免疫检查点抑制剂已成为肿瘤免疫治疗的一大热点。目前关于程序性细胞死亡蛋白(programmed cell death-1,PD-1)及其配体(programmed cell death ligand 1,PD-L1)、细胞毒性T淋巴细胞相关抗原-4(cytotoxic T lymphocyte associated antigen 4,CTLA-4)等通路抑制剂在非小细胞肺癌中开展了相关研究,且FDA批准一种PD-1抑制剂用于非小细胞肺癌的二线治疗,前景较为乐观。针对免疫检查点抑制剂在非小细胞肺癌中的应用作论述。The prognosis of non-small cell lung cancer（NSCLC） remains poor in recent years. But checkpoint inhibitors have already raised much attention in the immunotherapy of cancer. Now there are lots of researches on programmed cell death-1（PD-1）, programmed cell death ligand 1（PD-L1）, and cytotoxic T lymphocyte associated antigen 4（CTLA-4） inhibitors among the NSCLC patients. Recently, Nivolumab, a kind of PD-1 inhibitor, has already been approved in the second line therapy of NSCLC by FDA, which shows a good prospect. In this article, we make a review on the checkpoint inhibitors for the treatment of NSCLC.

关 键 词：非小细胞肺癌 免疫检查点抑制剂 程序性细胞死亡蛋白 程序性细胞死亡蛋白配体 细胞毒性T淋巴细胞相关抗原-4 

分 类 号：R734.2[医药卫生—肿瘤]